Kelly Bock, NP
Family · Bridge City, TXNPI 1205121548
Payments from drug & device makers
Across 93 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$332
- Novo Nordisk$211
- AstraZeneca$173
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Lilly USA, LLC$102
- Esperion Therapeutics, Inc.$58
- plus $458 from 15 others
What the payments were for
- Food & beverage$1,459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $332 |
| Novo Nordisk | 16 | $211 |
| AstraZeneca | 12 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $125 |
| Lilly USA, LLC | 7 | $102 |
| Esperion Therapeutics, Inc. | 4 | $58 |
| Boehringer Ingelheim | 3 | $50 |
| GSK | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 3 | $42 |
| Merck | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Bayer | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Amgen | 2 | $29 |
| Lundbeck LLC | 1 | $20 |
| IBSA Pharma Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $11 |
How this compares
$1,459 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 44 | $28,715 |
| EliquisApixaban | 29 | $21,063 |
| MounjaroTirzepatide | 18 | $19,197 |
| RybelsusSemaglutide | 16 | $18,192 |
| LinzessLinaclotide | 18 | $14,706 |
| MyrbetriqMirabegron | 17 | $14,390 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,715 |
| BelsomraSuvorexant | 18 | $7,765 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 11 | $6,918 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,105 |
| VascepaIcosapent Ethyl | 12 | $4,085 |
| Diazepam | 11 | $2,972 |
| Atorvastatin Calcium | 147 | $1,750 |
| Levothyroxine Sodium | 125 | $1,432 |
| Gabapentin | 98 | $1,422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $173 | $28,71544 claims |
| Lilly USA, LLCMounjaro | $102 | $19,19718 claims |
| Novo NordiskRybelsus | $211 | $18,19216 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $44 | $16,82031 claims |
| AbbVieLinzess | $332 | $14,70618 claims |
| MerckBelsomra | $41 | $7,76518 claims |
| Boehringer IngelheimTrijardy Xr | $50 | $6,91811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.
Other family in Bridge City
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.